A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model

A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02094365

Enrollment

Registered

2014-03-21

Start date

2014-03-31

Completion date

2014-07-31

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Syncytial Virus Infections

Brief summary

This study is designed to compare the antiviral effect of ALS-008176 compared to a placebo control in the respiratory syncytial virus challenge model.

Interventions

DRUGALS-008176

DRUGvehicle

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Age 18 to 45 years, inclusive. * In good health with no history of major medical conditions * A total body weight ≥ 50 kg and a body mass index (BMI) of \> 18kg/m2.

Exclusion criteria

* Acute or chronic medical illness * Positive for Human Immunodeficiency Virus, Hepatitis B or C * Nose or nasopharynx abnormalities * Abnormal lung function

Design outcomes

Primary

Measure	Time frame
Change in viral load measurements.	Baseline to day 12

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026